MYGN - MYRIAD GENETICS INC
4.5
0.140 3.111%
Share volume: 1,176,544
Last Updated: 03-31-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
0.03%
PREVIOUS CLOSE
CHG
CHG%
$4.36
0.14
0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-08-2024 | 08-07-2024 | 11-08-2024 | 02-28-2025 | 05-07-2025 | 08-06-2025 | 11-04-2025 | 02-24-2026 | |
| Assets | |||||||||
| Total Assets | 1.111 B | 1.085 B | 1.081 B | 1.028 B | 1.006 B | 677.300 M | 728.100 M | 706.600 M | |
| Current Assets | 290.300 M | 291.600 M | 293.200 M | 298.000 M | 287.200 M | 284.300 M | 344.800 M | 332.600 M | |
| Inventories | 24.600 M | 26.100 M | 26.200 M | 27.500 M | 28.300 M | 28.700 M | 31.600 M | 30.600 M | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 7.400 M | 4.900 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 96.900 M | 92.400 M | 99.900 M | 102.400 M | 91.800 M | 74.400 M | 145.400 M | 149.600 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 118.500 M | 116.300 M | 115.400 M | 117.400 M | 114.000 M | 113.000 M | 111.400 M | 114.000 M | |
| Other Assets | 701.700 M | 677.200 M | 672.700 M | 612.200 M | 604.900 M | 280.000 M | 271.900 M | 260.000 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.111 B | 1.085 B | 1.081 B | 1.028 B | 1.006 B | 677.300 M | 728.100 M | 706.600 M | |
| Total liabilities | 350.500 M | 344.600 M | 349.600 M | 326.500 M | 301.200 M | 289.200 M | 355.300 M | 338.600 M | |
| Total current liabilities | 146.100 M | 148.900 M | 154.300 M | 164.100 M | 151.100 M | 199.900 M | 148.000 M | 133.800 M | |
| Accounts Payable | 33.100 M | 33.300 M | 29.600 M | 32.300 M | 28.100 M | 30.900 M | 31.800 M | 30.000 M | |
| Other liabilities | 134.900 M | 125.800 M | 124.900 M | 90.100 M | 89.400 M | 88.100 M | 86.600 M | 84.700 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 38.700 M | 38.800 M | 39.000 M | 39.600 M | 59.300 M | 0.000 | 119.500 M | 119.900 M | |
| Other liabilities | 134.900 M | 125.800 M | 124.900 M | 90.100 M | 89.400 M | 88.100 M | 86.600 M | 84.700 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 760.000 M | 740.500 M | 731.700 M | 701.100 M | 704.900 M | 388.100 M | 372.800 M | 368.000 M | |
| Common stock | 1.420 B | 1.437 B | 1.446 B | 1.459 B | 1.462 B | 1.476 B | 1.488 B | 1.490 B | |
| Retained earnings | -655.500 M | -692.200 M | -714.300 M | -756.800 M | -756.900 M | -1.087 B | -1.115 B | -1.123 B |